Here's How Trump's Drug Deals Are Likely to Impact Healthcare ETFs
President Trump expanded drug-pricing agreements with 9 international companies, including Alcon and Teva, adding to 17 prior deals with firms like Pfizer. The MFN framework now covers 89% of the branded drug market. The impact on healthcare ETFs is mixed, with potential benefits for insurers (IHF) and uncertain effects on U.S. pharma (PPH).
How this was made
The 30-second read
Why it matters
The policy aims to lower Medicaid drug costs but creates mixed effects for insurers, PBMs, and pharma companies.
Market read
The new MFN deals reshape pricing expectations for U.S. drug markets, influencing both providers and manufacturers.
What to watch
Potential for tariff relief and increased U.S. manufacturing incentives may benefit some participants.
Background
The Trump administration expanded its Most‑Favoured‑Nation drug‑pricing framework to include nine additional foreign‑headquartered companies.
Ticker impact
Alcon is one of the foreign firms entering the MFN drug‑pricing agreements announced by the Trump administration.
Modest downside pressure on stock.
MFN pricing may reduce margins but could open U.S. market share.
Teva is included in the new MFN framework covering 89% of the branded drug market.
Short‑term price pressure.
Lower Medicaid pricing may compress Teva's U.S. earnings.
UCB joins the latest tranche of foreign drugmakers under the MFN agreements.
Slight downside risk.
Policy may limit pricing power in the U.S. market.
Market effects
Healthcare providers and PBMs may benefit from lower drug costs, while U.S. pharma faces margin pressure.
U.S. market sees policy shift; foreign drugmakers gain access to U.S. Medicaid pricing.
Broad impact on global pharma supply chain and pricing dynamics.
Counterpoint
Lower drug prices could boost volume and market share for foreign manufacturers, offsetting margin hits.
Key entities
- political figureDonald Trump
U.S. President announcing the MFN agreements.
- ETFiShares U.S. Healthcare Providers ETF
Potential beneficiary of lower drug costs.
- ETFVanEck Pharmaceutical ETF
Tracks U.S. pharma exposure, may face mixed impact.
